We have observed
14 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after October 17, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
CD89 ACTIVATION IN THERAPY
Sugar compositions for treating hemophilia a and/or von willebrand disease
INHIBITORY ANTI -FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
VON WILLEBRAND FACTOR VARIANTS HAVING IMPROVED FACTOR VIII BINDING AFFINITY
TREATMENT OF MUCOSITIS WITH IMMUNOGLOBULIN
PREVENTION OF INFECTION
COMPOSITIONS COMPRISING SECRETORY-LIKE IMMUNOGLOBULINS
PROCESS FOR ENRICHING IGA
SUGAR COMPOSITIONS FOR TREATING HEMOPHILIA A AND/OR VON WILLEBRAND DISEASE
NEBULIZATION OF IMMUNOGLOBULIN
PHARMACEUTICAL PRODUCT WITH INCREASED STABILITY COMPRISING IMMUNOGLOBULINS